Suzetrigine is a CYP3A Inducer, Not an Inhibitor
No, suzetrigine is not a CYP3A inhibitor—it is a CYP3A inducer. This is a critical distinction that directly impacts drug-drug interaction management and dosing decisions when prescribing this novel analgesic.
Mechanism and Clinical Implications
Suzetrigine acts as a CYP3A inducer, meaning it increases the metabolic activity of the CYP3A enzyme system 1, 2. This pharmacokinetic property has important clinical consequences:
Key Drug Interactions
When suzetrigine is combined with CYP3A substrates, caution is required because suzetrigine will accelerate their metabolism, potentially reducing their plasma concentrations and therapeutic efficacy 1. This is the opposite effect of what a CYP3A inhibitor would cause.
Practical Management Considerations
- Monitor CYP3A substrate drugs closely when initiating or discontinuing suzetrigine, as their plasma levels may decrease during concurrent use
- Conversely, be aware that strong CYP3A inhibitors or inducers can alter suzetrigine's own metabolism, requiring dosage adjustments 2
- Concomitant medications must be carefully assessed before prescribing suzetrigine, as CYP3A inhibitors or inducers can change dosing requirements or even contraindicate use 2
Additional Pharmacokinetic Considerations
Beyond its role as a CYP3A inducer, suzetrigine requires:
- Dosage adjustment in hepatic or renal impairment 1, 3
- Loading dose administration on an empty stomach (100 mg loading dose followed by 50 mg maintenance) 2
- Careful evaluation of hepatic-impairment precautions given its CYP3A-mediated interactions 3
Common Pitfall to Avoid
The most critical error would be confusing suzetrigine's inducer properties with inhibitor properties. As an inducer, it decreases (not increases) the plasma concentrations of co-administered CYP3A substrates. This is fundamentally different from drugs like clarithromycin, erythromycin, or ketoconazole, which are CYP3A inhibitors that increase substrate drug levels 4, 5.